TB-500: how it got to PCAC

Background

TB-500 is the name attached, primarily by compounding markets, to a synthetic peptide consisting of seven amino acids (LKKTETQ) understood to correspond to an active region of full-length thymosin β4 (Esposito et al. 2012, Anal Chim Acta). Full-length thymosin β4 is a 44-residue endogenous regenerative peptide first characterized in the 1980s and reviewed in detail by Goldstein and colleagues (Goldstein et al. 2012, Expert Opin Biol Ther). The two molecules — full-length thymosin β4 and the TB-500 fragment — are distinct chemical entities and have different regulatory histories. This page concerns the fragment marketed as TB-500, which is the substance scheduled for PCAC review on July 23, 2026.

Origin and identification

The Goldstein review documented that thymosin β4 was originally isolated from calf thymus and was later identified as one of the most abundant intracellular peptides in mammalian cells. The “active site” framing — the basis for the LKKTETQ fragment commercialized as TB-500 — was characterized in the late 1990s and early 2000s by groups examining which subdomain of thymosin β4 retained actin-binding and cell-migration activity in vitro. The Goldstein review noted the regenerative properties reported for full-length thymosin β4 in dermal, corneal, and cardiac models, and outlined the rationale for early-phase clinical trials of full-length material.

The Esposito et al. 2012 paper observed, in the context of developing a doping-control analytical method, that TB-500 was being marketed and used in horse racing, and reported that the substance appeared on the World Anti-Doping Agency prohibited list for human sport.

Distinction from RGN-259 / full-length thymosin β4

The synthetic fragment marketed as TB-500 is not the same substance as RGN-259, the ophthalmic formulation of full-length thymosin β4 developed by ReGenTree, LLC. RGN-259 is a recombinant 44-residue peptide that has been the subject of registered FDA-overseen Phase II and Phase III trials in dry eye disease and neurotrophic keratopathy (NCT02974907). The PCAC docket scheduled for July 23, 2026 concerns the LKKTETQ fragment, sold in U.S. compounding markets as TB-500, not RGN-259 and not full-length thymosin β4 marketed under any other identifier.

Regulatory journey

There is no FDA-approved drug containing TB-500 as an active ingredient, and no public NDA or BLA filing is associated with the synthetic fragment. The substance has, however, been the subject of two parallel regulatory developments.

In the international anti-doping context, the Esposito 2012 paper documented the inclusion of TB-500 on the World Anti-Doping Agency prohibited list. WADA inclusion has no direct U.S. legal effect, but it influenced subsequent pharmacy and laboratory practices around the substance.

In the U.S. compounding context, TB-500 was nominated for inclusion on the 503A bulks list during FDA’s evaluation of bulk drug substances. In 2023, FDA placed TB-500 in Category 2 of its interim 503A policy — the category for substances that “may present significant safety risks” and that may not be compounded under section 503A pending further evaluation (FDA Category 2 reference). The FDA cited concerns about peptide identity, impurities, immunogenicity, and the limited published human safety data.

In April 2026, FDA announced that the original Category 2 nomination had been withdrawn by the nominator and that, on the basis of a new nomination, TB-500 (free base and acetate) would be re-considered at the July 23, 2026 PCAC meeting (FDA July 23-24, 2026 PCAC announcement). STAT News reported that the agenda emerged in the context of public statements from senior HHS leadership favoring broader access to compounded peptides (STAT News, April 15, 2026).

What the July 23, 2026 meeting will consider

The July 2026 PCAC docket asks committee members to vote on whether TB-500 (free base and acetate) should be included on the 503A bulks list. The relevant FDA briefing document, expected to be posted to the meeting’s web page two business days before the meeting, will present FDA review staff’s evaluation of the substance under the agency’s standard 503A criteria: physical and chemical characterization, evidence of safety, evidence of effectiveness, historical use in compounding, and any FDA staff recommendation. Public comments may be filed in docket FDA-2025-N-6895 through July 22, 2026.

Coverage notes

The TB-500 literature is dominated by preclinical and analytical work; controlled human trial data on the LKKTETQ fragment is essentially absent. Published clinical evidence for the full-length thymosin β4 molecule does not, on its own, support efficacy or safety claims for the TB-500 fragment, because the two molecules are chemically distinct. This page will be updated after the July 23, 2026 PCAC meeting with the actual briefing document, FDA staff recommendation, and committee vote.